| content | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
VUF-6002
|
|
| Systematic (IUPAC) name | |
| 5-Chloro-2-[(4-methylpiperazin-1-yl)carbonyl]-1H-benzimidazole | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C13H15ClN4O |
| Mol. mass | 278.737 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
VUF-6002 (JNJ 10191584) is a drug which acts as a potent and selective antagonist at the histamine H4 receptor.1 It has antiinflammatory and analgesic effects in animal studies of acute inflammation.2
References
- ^ Zhang M, Thurmond RL, Dunford PJ. The histamine H(4) receptor: a novel modulator of inflammatory and immune disorders. Pharmacology and Therapeutics. 2007 Mar;113(3):594-606. PMID 17275092
- ^ Coruzzi G, Adami M, Guaita E, de Esch IJ, Leurs R. Antiinflammatory and antinociceptive effects of the selective histamine H4-receptor antagonists JNJ7777120 and VUF6002 in a rat model of carrageenan-induced acute inflammation. European Journal of Pharmacology. 2007 Jun 1;563(1-3):240-4. PMID 17382315
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
